9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Incidence and Predictors of Atrial Fibrillation Progression

      research-article
      , MD, PhD 1 , 2 , 3 , , PhD 1 , 2 , , MD 1 , 2 , , MD 1 , 2 , , MD 2 , 4 , , MD 5 , , MD 6 , , MD, PhD 7 , , MD 8 , , MD 9 , , MD 10 , , MD 11 , , MD 12 , , MD 13 , , BSc 2 , , MD 1 , 2 , , MD 4 , , PhD, MPH 14 , , MD 1 , 2 , , MD 1 , 2 , , MD 1 , 2 , , MD, MPH 1 , 2 , 15 , , for the Swiss‐AF Investigators
      Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
      John Wiley and Sons Inc.
      atrial fibrillation, epidemiology, predictors, progression, rhythm control, Atrial Fibrillation, Epidemiology

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The incidence and predictors of atrial fibrillation ( AF) progression are currently not well defined, and clinical AF progression partly overlaps with rhythm control interventions ( RCIs).

          Methods and Results

          We assessed AF type and intercurrent RCIs during yearly follow‐ups in 2869 prospectively followed patients with paroxysmal or persistent AF. Clinical AF progression was defined as progression from paroxysmal to nonparoxysmal or from persistent to permanent AF. An RCI was defined as pulmonary vein isolation, electrical cardioversion, or new treatment with amiodarone. During a median follow‐up of 3 years, the incidence of clinical AF progression was 5.2 per 100 patient‐years, and 10.9 per 100 patient‐years for any RCI. Significant predictors for AF progression were body mass index (hazard ratio [ HR], 1.03; 95% CI, 1.01–1.05), heart rate ( HR per 5 beats/min increase, 1.05; 95% CI, 1.02–1.08), age ( HR per 5‐year increase 1.19; 95% CI, 1.13–1.27), systolic blood pressure ( HR per 5 mm Hg increase, 1.03; 95% CI, 1.00–1.05), history of hyperthyroidism ( HR, 1.71; 95% CI, 1.16–2.52), stroke ( HR, 1.50; 95% CI, 1.19–1.88), and heart failure ( HR, 1.69; 95% CI, 1.34–2.13). Regular physical activity ( HR, 0.80; 95% CI, 0.66–0.98) and previous pulmonary vein isolation ( HR, 0.69; 95% CI, 0.53–0.90) showed an inverse association. Significant predictive factors for RCIs were physical activity ( HR, 1.42; 95% CI, 1.20–1.68), AF‐related symptoms ( HR, 1.84; 95% CI, 1.47–2.30), age ( HR per 5‐year increase, 0.88; 95% CI, 0.85–0.92), and paroxysmal AF ( HR, 0.61; 95% CI, 0.51–0.73).

          Conclusions

          Cardiovascular risk factors and comorbidities were key predictors of clinical AF progression. A healthy lifestyle may therefore reduce the risk of AF progression.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction.

          Atrial fibrillation (AF) and heart failure (HF) frequently coexist and together confer an adverse prognosis. The association of AF with HF subtypes has not been well described. We sought to examine differences in the temporal association of AF and HF with preserved versus reduced ejection fraction.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.

            Though atrial fibrillation (AF) is an important cause of cardiovascular morbidity, there are few large epidemiological studies of its prevalence, incidence, and risk factors. The epidemiological features of AF are described in one of the largest population cohorts ever studied. The prevalence and incidence of AF were studied in the Renfrew/Paisley population cohort of 15 406 men and women aged 45-64 years living in the west of Scotland. This cohort was initially screened between 1972 and 1976 and again between 1977 and 1979. Incident hospitalisations with AF in the 20 year period following initial screening were also studied. The population prevalence of AF in this cohort was 6.5 cases/1000 examinations. Prevalence was higher in men and older subjects. In those who were rescreened, the four year incidence of AF was 0.54 cases/1000 person years. Radiological cardiomegaly was the most powerful predictor of new AF (adjusted odds ratio 14.0). During 20 year follow up, 3.5% of this cohort was discharged from hospital with a diagnosis of AF; the rate of incident hospitalisation for AF was 1.9 cases/1000 person years. Radiological cardiomegaly (adjusted odds ratio 1.46) and systolic blood pressure (adjusted odds ratio 2.1 for >/= 169 mm Hg) were independent predictors of this outcome. Data from one of the largest epidemiological studies ever undertaken confirm that AF has a large population prevalence and incidence, even in middle aged people. More important, it was shown that the long term incidence of hospitalisation related to AF is high and that two simple clinical measurements are highly predictive of incident AF. These findings have important implications for the prevention of AF.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF

              Aims The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. Methods and results GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. Conclusion The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. Clinical Trial Registration http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
                Bookmark

                Author and article information

                Contributors
                conend@mcmaster.ca
                Journal
                J Am Heart Assoc
                J Am Heart Assoc
                10.1002/(ISSN)2047-9980
                JAH3
                ahaoa
                Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
                John Wiley and Sons Inc. (Hoboken )
                2047-9980
                08 October 2019
                15 October 2019
                : 8
                : 20 ( doiID: 10.1002/jah3.v8.20 )
                : e012554
                Affiliations
                [ 1 ] Division of Cardiology Department of Medicine University Hospital Basel University of Basel Basel Switzerland
                [ 2 ] Cardiovascular Research Institute Basel University Hospital Basel University of Basel Basel Switzerland
                [ 3 ] Division of Internal Medicine Department of Medicine University Hospital Basel University of Basel Basel Switzerland
                [ 4 ] Division of Cardiology Department of Medicine Inselspital Bern University Hospital University of Bern Switzerland
                [ 5 ] Department of Medicine Cantonal Hospital of Baden and Molecular Cardiology University Hospital of Zurich Zurich Switzerland
                [ 6 ] Division of Cardiology Kantonsspital St. Gallen St. Gallen Switzerland
                [ 7 ] Division of Cardiology Fondazione Cardiocentro Ticino Lugano Switzerland
                [ 8 ] Division of Cardiology Luzerner Kantonsspital Luzern Switzerland
                [ 9 ] Laboratory for Signal Transduction Department of Biomedicine University of Basel Basel Switzerland
                [ 10 ] Division of Cardiology Ospedale Regionale di Lugano Lugano Ticino Switzerland
                [ 11 ] Division of Cardiology Ospedale San Giovanni Bellinzona Bellinzona Ticino Switzerland
                [ 12 ] Division of Cardiology University Hospital Geneva Geneva Switzerland
                [ 13 ] Service of Cardiology University Hospital Lausanne Lausanne Switzerland
                [ 14 ] Epidemiology, Biostatistics and Prevention Institute University of Zurich Switzerland
                [ 15 ] Population Health Research Institute McMaster University Hamilton Ontario Canada
                Author notes
                [*] [* ] Correspondence to: David Conen, MD, MPH, Population Health Research Institute, Barton Street East, Hamilton, Ontario, Canada. E‐mail: conend@ 123456mcmaster.ca
                [†]

                A complete list of the Swiss‐AF Investigators can be found in the Supplemental Material.

                Article
                JAH34475
                10.1161/JAHA.119.012554
                6818023
                31590581
                f40f41b7-62e0-4126-af98-8df6be98f45d
                © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 08 March 2019
                : 21 August 2019
                Page count
                Figures: 2, Tables: 3, Pages: 9, Words: 7636
                Funding
                Funded by: Swiss National Science Foundation
                Award ID: PP00P3_159322
                Award ID: 33CS30_1148474
                Award ID: 33CS30_177520
                Funded by: Swiss Heart Foundation
                Funded by: University of Basel
                Funded by: Boehringer Ingelheim
                Funded by: Sanofi‐Aventis
                Funded by: Merck Sharp & Dome
                Funded by: Bayer
                Funded by: Daiichi‐Sankyo,
                Funded by: Pfizer
                Funded by: Bristol‐Myers Squibb
                Funded by: Foundation for Cardiovascular Research Basel,
                Funded by: Hamilton Health Sciences RFA Strategic Initiative Program
                Categories
                Original Research
                Original Research
                Arrhythmia and Electrophysiology
                Custom metadata
                2.0
                jah34475
                15 October 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.7.0 mode:remove_FC converted:15.10.2019

                Cardiovascular Medicine
                atrial fibrillation,epidemiology,predictors,progression,rhythm control
                Cardiovascular Medicine
                atrial fibrillation, epidemiology, predictors, progression, rhythm control

                Comments

                Comment on this article